<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190708044138N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-07</date_registration>
      <primary_sponsor>Urmia University</primary_sponsor>
      <public_title>Effect of transcranial direct current stimulation and high definition stimulation on restless leg syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of transcranial direct current stimulation (tDCS) and high definition stimulation (HD-tDCS) on cognitive-psychological symptoms in adults with restless leg syndrome (RLS)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40638</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization will be done using www.randomization.com to assign equal participants in each group (1:1 allocation ). An independent researcher will make random allocation cards using computer-generated random numbers. he will keep the original random allocation sequences until analysis time. Another independent researcher will measure the patients outcome and she will not know the allocation, Blinding description: The neuroscientist of Yazd Psychological Center will be aware of the research topic and will perform therapeutic interventions. He codes the patients and refers them to a psychologist to check the patient's mental state and record the relevant criteria based on the same code. The patients will be tested in the same condition in the neurotherapy room and the electrodes of the device will be connected to them, but they will not be aware of the real or sham stimulation. Accordingly, this study will be a double-blind study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>restless legs syndrome.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group received transcranial direct current stimulation (HD-tDCS) at 4 mA (positive or anode stimulation) over 10 consecutive sessions (25 minutes per session). Intervention 2: The second intervention group received high definition-transcranial direct current stimulation (HD-tDCS) at 2 mA (positive or anode stimulation) over 10 consecutive sessions (25 minutes per session). Intervention 3: The first control group received high definition-transcranial direct current stimulation (HD-tDCS) with Sham over 10 consecutive sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Participant Data File: Because the individual data of the study participants are considered, this study shares some of the data such as information about the main outcomes of the study.

When:
The access period starts 9 months after the results are published.

To whom:
The data obtained from this study are only available to researchers working at Urmia University snd Shahid Sadoughi University of Medical Sciences.

Conditions:
The data of this study are only permitted for correlation analysis and independent t-test.

Where to obtain:
Visit Mr. Mohammad Hossein Sorbi from Urmia University, or contact him by email or phone.
Phone: 09131560290, Email: Sorbih@gmail.com

How to obtain:
Applicants are required to notify Mr. Sorbi by phone or email 9 months after the results of the study are published. Next, the data will be delivered in person.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Sorbi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eleven kilometers of University Boulevard</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5756151818</zip>
        <telephone>+98 44 3275 2741</telephone>
        <email>sorbih@gmail.com</email>
        <affiliation>Urmia University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Esazadegan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eleven kilometers of University Boulevard</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5756151818</zip>
        <telephone>009832752741</telephone>
        <email>a.esazade@gmail.com</email>
        <affiliation>Urmia University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of restless legs syndrome by a psychiatrist or psychologist
Gaining  moderate to high score in severity of the syndrome (scores of 5 to 12) in the international restless legs syndrome questionnaire
Rejecting differential diagnosis of neuro-motor disorder by a neurologist and absence of neurological disorder
Aged between 18 to 75 years
Not suffering from cardiovascular disease, kidney disease and diabetes (getting information  by asking from participants and get help from a physician)
Not Smoking and not taking painkillers, sedatives and hypnotics
Non-pregnancy in women</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 months</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Dissatisfaction to participate in the research
Having a type of motor or cognitive disabilities that interferes working with computer
Receiving simultaneous psychiatric treatment or other psychotherapies to relieve RLS symptoms
History of seizure disorders in individuals, having a pacemaker, having a metal object in the head and neck or any other obstacle to do electrical stimulation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G25.81</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Restless legs syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group received transcranial direct current stimulation (HD-tDCS) at 4 mA (positive or anode stimulation) over 10 consecutive sessions (25 minutes per session).</i_keyword>
      <i_keyword>The second intervention group received high definition-transcranial direct current stimulation (HD-tDCS) at 2 mA (positive or anode stimulation) over 10 consecutive sessions (25 minutes per session).</i_keyword>
      <i_keyword>The first control group received high definition-transcranial direct current stimulation (HD-tDCS) with Sham over 10 consecutive sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cognitive Symptoms. Timepoint: Cognitive Symptoms was measured at the beginning of the study (before the intervention), after the last treatment session, and 30 days (one month) after the last treatment session. Method of measurement: The Integrated Visual and Auditory (IVA-2).</prim_outcome>
      <prim_outcome>Depression. Timepoint: Depression was measured at the beginning of the study (before the intervention), after the last treatment session, and 30 days (one month) after the last treatment session. Method of measurement: beck depression inventory (BDI-II).</prim_outcome>
      <prim_outcome>Severity of Restless Legs Syndrome. Timepoint: Severity of Restless Legs Syndrome was measured at the beginning of the study (before the intervention), after the last treatment session, and 30 days (one month) after the last treatment session. Method of measurement: International Restless Legs Syndrome Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Urmia University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-25</approval_date>
        <contact_name>Ethics committee of Shahid Sadoughi University of Medical Sciences</contact_name>
        <contact_address>Central Administration, Bahonar Sq., Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
